<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2019//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_190101.dtd">
<PubmedArticleSet>
<PubmedArticle>
    <MedlineCitation Status="MEDLINE" Owner="NLM">
        <PMID Version="1">17279403</PMID>
        <DateCompleted>
            <Year>2007</Year>
            <Month>12</Month>
            <Day>06</Day>
        </DateCompleted>
        <DateRevised>
            <Year>2018</Year>
            <Month>11</Month>
            <Day>13</Day>
        </DateRevised>
        <Article PubModel="Print-Electronic">
            <Journal>
                <ISSN IssnType="Print">1618-7598</ISSN>
                <JournalIssue CitedMedium="Print">
                    <Volume>8</Volume>
                    <Issue>3</Issue>
                    <PubDate>
                        <Year>2007</Year>
                        <Month>Sep</Month>
                    </PubDate>
                </JournalIssue>
                <Title>The European journal of health economics : HEPAC : health economics in prevention and care</Title>
                <ISOAbbreviation>Eur J Health Econ</ISOAbbreviation>
            </Journal>
            <ArticleTitle>Patient access to pharmaceuticals: an international comparison.</ArticleTitle>
            <Pagination>
                <MedlinePgn>253-66</MedlinePgn>
            </Pagination>
            <Abstract>
                <AbstractText>We have identified eight sub-dimensions of patient access to pharmaceuticals: marketing approvals, time of marketing approval, coverage, cost sharing, conditions of reimbursement, speed from marketing approval to reimbursement, extent to which beneficiaries control choice of their drug benefit, and evenness of the availability of drugs to the population. For a sample of commonly used best-selling drugs in the United States (US), we measured these eight access sub-dimensions across four health systems: France, the Netherlands, the United Kingdom (UK), and the US. Although the US approved between 15 and 18% more drugs than the other three countries, the US was slower than France and the UK to approve drugs licensed in all four countries. The percentage of drugs covered is approximately the same for all four countries. For covered drugs, we observe the least cost sharing by patients in the Netherlands. The Netherlands imposes conditions of reimbursement on a much larger percentage of drugs. France seems to be the slowest in respect of speed from marketing approval to reimbursement. The US is the most flexible in terms of the extent to which beneficiaries control their choice of drug benefit but it is the least universal in terms of evenness of the availability of drugs to the population. Our study confirms the frequently cited problems of access in European countries: lag between marketing approval and reimbursement, and inflexibility in respect of the extent to which beneficiaries control their choice of drug benefit. At the same time, our study confirms, qualitatively, different kinds of access problems in the US: relatively high patient cost sharing for pharmaceuticals, and wide variation in coverage.</AbstractText>
            </Abstract>
            <AuthorList CompleteYN="Y">
                <Author ValidYN="Y">
                    <LastName>Cohen</LastName>
                    <ForeName>Joshua</ForeName>
                    <Initials>J</Initials>
                    <AffiliationInfo>
                        <Affiliation>Tufts Center for the Study of Drug Development, Boston, MA 02111, USA. joshua.cohen@tufts.edu</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Faden</LastName>
                    <ForeName>Laura</ForeName>
                    <Initials>L</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Predaris</LastName>
                    <ForeName>Susan</ForeName>
                    <Initials>S</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Young</LastName>
                    <ForeName>Brian</ForeName>
                    <Initials>B</Initials>
                </Author>
            </AuthorList>
            <Language>eng</Language>
            <PublicationTypeList>
                <PublicationType UI="D003160">Comparative Study</PublicationType>
                <PublicationType UI="D016428">Journal Article</PublicationType>
            </PublicationTypeList>
            <ArticleDate DateType="Electronic">
                <Year>2007</Year>
                <Month>02</Month>
                <Day>06</Day>
            </ArticleDate>
        </Article>
        <MedlineJournalInfo>
            <Country>Germany</Country>
            <MedlineTA>Eur J Health Econ</MedlineTA>
            <NlmUniqueID>101134867</NlmUniqueID>
            <ISSNLinking>1618-7598</ISSNLinking>
        </MedlineJournalInfo>
        <CitationSubset>IM</CitationSubset>
        <MeshHeadingList>
            <MeshHeading>
                <DescriptorName UI="D017047" MajorTopicYN="N">Cost Sharing</DescriptorName>
                <QualifierName UI="Q000706" MajorTopicYN="N">statistics &amp; numerical data</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D017277" MajorTopicYN="N">Drug Approval</DescriptorName>
                <QualifierName UI="Q000191" MajorTopicYN="N">economics</QualifierName>
                <QualifierName UI="Q000331" MajorTopicYN="Y">legislation &amp; jurisprudence</QualifierName>
                <QualifierName UI="Q000458" MajorTopicYN="N">organization &amp; administration</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D011307" MajorTopicYN="N">Drug Prescriptions</DescriptorName>
                <QualifierName UI="Q000145" MajorTopicYN="N">classification</QualifierName>
                <QualifierName UI="Q000191" MajorTopicYN="N">economics</QualifierName>
                <QualifierName UI="Q000706" MajorTopicYN="Y">statistics &amp; numerical data</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D005569" MajorTopicYN="N">Formularies as Topic</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D005602" MajorTopicYN="N">France</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D017048" MajorTopicYN="N">Health Care Costs</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D006297" MajorTopicYN="N">Health Services Accessibility</DescriptorName>
                <QualifierName UI="Q000191" MajorTopicYN="N">economics</QualifierName>
                <QualifierName UI="Q000706" MajorTopicYN="Y">statistics &amp; numerical data</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D007349" MajorTopicYN="N">Insurance, Health, Reimbursement</DescriptorName>
                <QualifierName UI="Q000706" MajorTopicYN="Y">statistics &amp; numerical data</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D007356" MajorTopicYN="N">Insurance, Pharmaceutical Services</DescriptorName>
                <QualifierName UI="Q000706" MajorTopicYN="Y">statistics &amp; numerical data</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D038622" MajorTopicYN="N">Internationality</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D009426" MajorTopicYN="N">Netherlands</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D010358" MajorTopicYN="N">Patient Participation</DescriptorName>
                <QualifierName UI="Q000706" MajorTopicYN="N">statistics &amp; numerical data</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D010602" MajorTopicYN="N">Pharmacopoeias as Topic</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D013997" MajorTopicYN="N">Time Factors</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D006113" MajorTopicYN="N">United Kingdom</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D014481" MajorTopicYN="N">United States</DescriptorName>
            </MeshHeading>
        </MeshHeadingList>
    </MedlineCitation>
    <PubmedData>
        <History>
            <PubMedPubDate PubStatus="received">
                <Year>2006</Year>
                <Month>07</Month>
                <Day>19</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="accepted">
                <Year>2006</Year>
                <Month>11</Month>
                <Day>09</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="pubmed">
                <Year>2007</Year>
                <Month>2</Month>
                <Day>7</Day>
                <Hour>9</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="medline">
                <Year>2007</Year>
                <Month>12</Month>
                <Day>7</Day>
                <Hour>9</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="entrez">
                <Year>2007</Year>
                <Month>2</Month>
                <Day>7</Day>
                <Hour>9</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
        </History>
        <PublicationStatus>ppublish</PublicationStatus>
        <ArticleIdList>
            <ArticleId IdType="pubmed">17279403</ArticleId>
            <ArticleId IdType="doi">10.1007/s10198-006-0028-z</ArticleId>
        </ArticleIdList>
        <ReferenceList>
            <Reference>
                <Citation>J Health Econ. 2002 Sep;21(5):923-6</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">12349889</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Pharmacoeconomics. 1996;10 Suppl 2:26-36</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">10163433</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Am J Manag Care. 2004 May;10(5):308-12</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">15152700</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Pharmacoeconomics. 2001;19 Suppl 2:39-47</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">11700788</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>J Health Polit Policy Law. 2003 Aug;28(4):715-46</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">12956521</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Health Aff (Millwood). 2003 May-Jun;22(3):42-5</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">12757270</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>BMJ. 1999 Mar 6;318(7184):661-4</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">10066215</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Health Econ. 2005 Mar;14(3):269-92</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">15386651</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Health Policy. 2002 Jan;59(1):53-63</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">11786174</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Ned Tijdschr Geneeskd. 2002 Sep 14;146(37):1729-33</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">12357873</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Wall St J (East Ed). 2005 Nov 22;:A1, A11</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">16502534</ArticleId>
                </ArticleIdList>
            </Reference>
        </ReferenceList>
    </PubmedData>
</PubmedArticle>

</PubmedArticleSet>
